Innoviva (INVA) Deferred Taxes (2018 - 2026)
Innoviva's (INVA) quarterly Deferred Taxes came in at $41.0 million in Q1 2026, up 17199.17% YoY from N/an in Q1 2025, and up 907.81% on a QoQ basis from $4.1 million in Q3 2025.
Innoviva (INVA) Deferred Taxes (2018 - 2026) Analysis & Trends
Innoviva (INVA) has 9 years of Deferred Taxes data on file, last reported at $41.0 million in Q1 2026.
- Quarterly Deferred Taxes rose 17199.17% year-over-year to $41.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.2 million (up 259.76% YoY) and the FY2025 annual result came in at $43.8 million, up 447.52% from the prior year.
- Deferred Taxes grew to $41.0 million in Q1 2026, from $4.1 million in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $41.0 million in Q1 2026 to a low of -$15.4 million in Q3 2024.
- A 5-year average of $4.0 million and a median of -$240000.0 in 2025 frame the typical range for Deferred Taxes.
- Annual changes were most pronounced in 2024 — Deferred Taxes plunged 1284.57% — and 2026, when it soared 17199.17%.
- Tracing INVA's Deferred Taxes over 5 years: stood at $29.3 million in 2022, then slumped by 103.81% to -$1.1 million in 2023, then sank by 1284.57% to -$15.4 million in 2024, then soared by 126.38% to $4.1 million in 2025, then jumped by 907.81% to $41.0 million in 2026.
- The last three Deferred Taxes figures came in at $41.0 million (Q1 2026), $4.1 million (Q3 2025), and -$637000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | -36.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.09 Mn |
| Mar 31, 2026 | 41.04 Mn |
| Sep 30, 2025 | 4.07 Mn |
| Jun 30, 2025 | -637,000.00 |
| Mar 31, 2025 | -240,000.00 |
| Sep 30, 2024 | -15.44 Mn |
| Jun 30, 2024 | -15.25 Mn |
| Mar 31, 2024 | 3.24 Mn |
| Sep 30, 2023 | -1.12 Mn |
| Jun 30, 2023 | 1.35 Mn |
| Mar 31, 2023 | -812,000.00 |
| Sep 30, 2022 | 29.26 Mn |
| Jun 30, 2022 | -876,000.00 |
| Mar 31, 2022 | 6.86 Mn |
| Sep 30, 2021 | 65.60 Mn |
| Jun 30, 2021 | 25.33 Mn |
| Mar 31, 2021 | 19.74 Mn |
| Dec 31, 2020 | 15.73 Mn |
| Sep 30, 2020 | 8.87 Mn |
| Jun 30, 2020 | 19.89 Mn |